Adiponectin and Insulin Resistance in Diabetic Nephropathy

This study has been completed.
Sponsor:
Collaborator:
Shanghai Jiao Tong University School of Medicine
Information provided by:
Xi’an Jiaotong University College of Medicine
ClinicalTrials.gov Identifier:
NCT00774904
First received: October 16, 2008
Last updated: October 17, 2008
Last verified: October 2008
  Purpose

Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).


Condition Intervention
Diabetic Nephropathy
Drug: Losartan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan

Resource links provided by NLM:


Further study details as provided by Xi’an Jiaotong University College of Medicine:

Primary Outcome Measures:
  • GFR, HbA1c and the adiponectin concentration [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]

Enrollment: 80
Study Start Date: April 2007
Study Completion Date: November 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Losartan
    Angiotensin II Type 1 Receptor Blockers
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetic nephropathy
  • CKD at stage 1~4

Exclusion Criteria:

  • Type 1 diabetes or nondiabetic renal disease
  • An elevated plasma K level.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00774904

Locations
China
Shanghai No.3 people's hospital
Shanghai, China, 201900
Sponsors and Collaborators
Xi’an Jiaotong University College of Medicine
Shanghai Jiao Tong University School of Medicine
  More Information

No publications provided

Responsible Party: hui min Jin, shanghai No 3 people's hospital
ClinicalTrials.gov Identifier: NCT00774904     History of Changes
Other Study ID Numbers: ADPN
Study First Received: October 16, 2008
Last Updated: October 17, 2008
Health Authority: China: Food and Drug Administration

Keywords provided by Xi’an Jiaotong University College of Medicine:
Type 2 Diabetes
Diabetic Nephropathy
Glucose Metabolism
Angiotensin II Type 1 Receptor Blockers

Additional relevant MeSH terms:
Insulin Resistance
Diabetic Nephropathies
Kidney Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Losartan
Angiotensin II Type 1 Receptor Blockers
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 16, 2014